Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Comment by GiveMeMoneyon Nov 07, 2020 6:05pm
79 Views
Post# 31858352

RE:RE:RE:RE:FDA Approval for Investigational New Drug (IND) Application

RE:RE:RE:RE:FDA Approval for Investigational New Drug (IND) Application

This is not the end-all-and-be-all of co's nor stocks and anyone who's actually reading and, actually, studying how they are trying to add hype to their SP will ask themselves WHY?

Brokers and analyst's who have jumped in may ask themsleves just how much of the market they are betting against what the market is saying. Proof is in the pudding.

CRDL released to the market the fact that they had a deal with SD the minute their daily SP went towards $2, just toucing it, and didn't perform on it for 3 months (Mar to June) only to drop it after a week on the shelf: makes you wonder just what else we're going to see this kind of thing going on.  Credibility is in the toilet.

They have also not informed the market about the nature of their pships with their "manufacturers" who may in fact own the cortucal if this falls apart.

And, their SDrug retail prices are stupid. Lots of mouths to feed with that - to the shagrin of the viability of the actual product and whole marketing effort.

This co is not a mule, it's a drunk mule, and they certainly don't appreciate their shareholders.

"Next funding, please?"

<< Previous
Bullboard Posts
Next >>